Support MPCC

 

1 out of 36 men will die of prostate cancer. Get involved.

Our Mission

Our Mission

The Massachusetts Prostate Cancer Coalition (MPCC) educates, connects, and supports men-at-risk, newly diagnosed individuals, survivors, and their families. It also connects organizations and professionals in Massachusetts that seek to conquer and cure prostate cancer.

Our Vision: Educate | Inform | Advocate

 


 

 

Five Facts about Prostate Cancer

Five Facts about Prostate Cancer
  1. 1
    Prevalence
    Prostate cancer is the most common (non-skin) cancer in American men, representing 33% of all new cases.
  2. 2
    Prostate cancer affects 1 in 7 men.
    1 in 7 men will be diagnosed with prostate cancer during their lifetime. In 2015, nearly 6,000 men were diagnosed with prostate cancer in Massachusetts, with an incidence rate of 4%-6% higher than the national average.
  3. 3
    Second leading cause of cancer death in men.
    Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. 
  4. 4
    Prostate cancer top risk factors.

    Ethnicity

    African-American men are twice as likely to die of prostate cancer as white men. Asian-Americans and Hispanic/Latinos have lower rates of prostate cancer than non-Hispanic white men.

    Age

    Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66.

  5. 5
    This year over 29,000 men will die of prostate cancer.

    Yet, most men diagnosed with prostate cancer will not die from it. In fact, more than 2.5 million men in the United States who have been diagnosed with prostate cancer are still alive today.


Statistics from The American Cancer Society 2017

We need your support! Become a Member or Donate to MPCC today.

 

Sarm Prostate Cancer Study at Brigham and Women’s Hospital Go here to learn more.

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer. Read more read more →

They are among the most challenging prostate cancer patients to treat: about 150,000 men worldwide each year whose cancer is aggressive enough to defy standard hormonal therapy, but has not yet spread to the point where it can be seen on scans. Read more read more →